Daraxonrasib Phase 3 Results: A Survival Difference in Metastatic Pancreatic Cancer
In this article
Targeted Treatments Outperform Chemotherapy in Pancreatic Cancer: Daraxonrasib Phase 3 Data
Revolution Medicines Clinical Data Report, 13 April 2026 · Clinical Trial: NCT06625320 · Presentation: ASCO 2026 Annual Meeting (Scheduled)
On 13 April 2026, the oncology world witnessed some of the most impressive survival data in the history of pancreatic cancer. The advanced RAS(ON) inhibitor Daraxonrasib (RMC-6236), in the phase 3 RASolute 302 study, reduced the risk of death by 60% compared with standard chemotherapy and increased overall survival from 6.7 months to 13.2 months . These data prove that, for the first time, a nonchemotherapy option has established such dominant superiority in metastatic pancreatic cancer.
Pancreatic Cancer's Genetic Lock and RAS Inhibition
Pancreatic ductal adenocarcinoma (PDAC) is known as oncology's “toughest fortress.” The key to this fortress, mutated in more than 90% of cases, is RAS proteins. Considered “undruggable” for decades, RAS can now be blocked directly and effectively with daraxonrasib. What distinguishes daraxonrasib is that it targets not just a single specific RAS mutation, but the active forms, or ON state, of common mutations such as G12D, G12V, and G12R.
A Rigorous Academic Design: RASolute 302
RASolute 302 includes patients over 18 diagnosed with metastatic PDAC who had progressed on at least one line of systemic chemotherapy, usually FOLFIRINOX or gemcitabine/nab-paclitaxel.
Daraxonrasib's Superiority Across the Data
The data obtained at the first interim analysis were so strong that the independent data monitoring committee designated them “final” efficacy results.
- Progression-Free Survival (PFS): A statistically significant improvement was recorded in the daraxonrasib group compared with chemotherapy.
- Overall Response Rate (ORR): As a targeted agent, it produced significantly greater tumor shrinkage than the chemotherapy group.
- Duration of Response (DOR): The durability of the responses obtained exceeded the short-lived effects of cytotoxic chemotherapy.
Safety and Tolerability: Oral Convenience Versus Chemotherapy
Quality of life (QOL) in pancreatic cancer is at least as critical as survival. While severe chemotherapy adverse effects, such as neutropenia, severe mucositis, and neuropathy, often bring patients to the point of stopping treatment, daraxonrasib offered a more manageable profile:
- ✅ No New Safety Signals: A profile consistent with phase 1 and 2 data.
- ✅ Fewer Hospitalizations: Oral administration allowed patients to receive treatment in the comfort of home.
- ✅ Manageable Adverse Effects: The most frequent were mild to moderate gastrointestinal symptoms and rash.
- ✅ Low Treatment Discontinuation Rate: Rates of drug discontinuation due to adverse effects were lower than with standard chemotherapy.
🎓 DROZDOGAN Academy — Scientific Commentary and Discussion
PDAC · RMC-6236 · THE FUTURE OF TARGETED THERAPIES
The Clinical Weight of the Data
A median OS of 13.2 months in pancreatic cancer is among the highest values achieved in second-line treatment to date. While exceeding 6 months in the second line is generally considered a success, daraxonrasib doubled that threshold. A hazard ratio as low as 0.40, in particular, proves that the drug's effect is not coincidental and provides very strong protection across the population.
A New Era for “RAS-Addicted” Tumors
Daraxonrasib offers hope not only for pancreatic cancer but also for RAS-dependent tumors such as lung and colorectal cancer. Described as “pioneering RAS(ON) inhibition,” this approach cuts off the cell's growth signal at its very center. Activity in patients with “wild-type,” nonmutated RAS also confirms the biological dominance of the RAS pathway in pancreatic cancer.
Critical Limitations and Expectations
Although this is a phase 3 study, the data come from the first interim analysis. Long-term follow-up will be vital, particularly for understanding whether resistance mechanisms develop. Furthermore, availability and reimbursement in countries such as Türkiye will be discussed in terms of cost-effectiveness. Scientifically, however, daraxonrasib currently stands as a “new standard-of-care candidate” (new SOC candidate) for pancreatic cancer.
Scientific Sources
- Revolution Medicines Press Release. Daraxonrasib demonstrates unprecedented overall survival benefit in pivotal phase 3 RASolute 302 clinical trial. April 13, 2026
- Wolpin BM. “Practice-changing results for patients with metastatic pancreatic cancer.” Dana-Farber Cancer Institute, Clinical News, April 2026.
- ClinicalTrials.gov. RASolute 302: Phase 3 Study of Daraxonrasib (RMC-6236) in Metastatic PDAC.
- ASCO 2026 Preview. Breaking Ground in GI Cancers: The Year of RAS Inhibition. Journal of Clinical Oncology (Supp), 2026.
This article was specifically structured for the Dr. Özdoğan platform using phase 3 clinical-trial data and global oncology reports published in April 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.